{
    "root": "f9b9e637-d236-4bc0-afca-bbbf1b1747ab",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Sevelamer Hydrochloride"
    },
    "value": "20250205",
    "ingredients": [
        {
            "name": "SEVELAMER HYDROCHLORIDE",
            "code": "GLS2PGI8QG"
        },
        {
            "name": "DIACETYLATED MONOGLYCERIDES",
            "code": "5Z17386USF"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 200 LM",
            "code": "VG6UJI79NF"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "sevelamer hydrochloride tablets indicated control serum phosphorus patients chronic kidney disease ( ckd ) dialysis . safety efficacy sevelamer hydrochloride tablets ckd patients dialysis studied .",
    "contraindications": "patients taking phosphate binder . recommended starting dose sevelamer hydrochloride tablets 800 mg 1600 mg orally , administered one two 800 mg sevelamer hydrochloride tablets meals based serum phosphorus level . table 1 provides recommended starting doses sevelamer hydrochloride tablets patients taking phosphate binder . table 1 : starting dose dialysis patients taking phosphate binder serum phosphorus sevelamer hydrochloride tablets 800 mg > 5.5 < 7.5 mg/dl 1 tablet three times daily meals ≥7.5 < 9.0 mg/dl 2 tablets three times daily meals ≥9.0 mg/dl 2 tablets three times daily meals patients switching calcium acetate . study 84 ckd patients hemodialysis , similar reduction serum phosphorus seen equivalent doses ( approximately mg mg ) sevelamer hydrochloride tablets calcium acetate . table 2 gives recommended starting doses sevelamer hydrochloride tablets based patient 's current calcium acetate dose . table 2 : starting dose dialysis patients switching calcium acetate sevelamer hydrochloride tablets calcium acetate 667 mg ( tablets per meal ) sevelamer hydrochloride tablets 800 mg ( tablets per meal ) 1 tablet 1 tablet 2 tablets 2 tablets 3 tablets 3 tablets dose titration patients taking sevelamer hydrochloride tablets . adjust based serum phosphorus concentration goal lowering serum phosphorus 5.5 mg/dl less . increase decrease one tablet per meal two-week intervals necessary . table 3 gives dose titration guideline . average dose phase 3 trial designed lower serum phosphorus 5.0 mg/dl less approximately three sevelamer hydrochloride 800 mg tablets per meal . maximum average daily sevelamer hydrochloride tablets dose studied 13 g. table 3 : dose titration guideline serum phosphorus sevelamer hydrochloride tablets dose > 5.5 mg/dl increase 1 tablet per meal 2-week intervals 3.5-5.5 mg/dl maintain current dose < 3.5 mg/dl decrease 1 tablet per meal",
    "warningsAndPrecautions": "sevelamer hydrochloride tablets supplied white off-white , oval shaped film-coated tablets , debossed `` nav `` one side debossed `` 110 `` side . sevelamer hydrochloride tablets 800 mg packaged bottles 180 tablets . 1 bottle 180 counts 800 mg tablets ( ndc 70710-2058-8 ) storage : store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) . sevelamer hydrochloride tablets expiration date bottle . [ usp controlled room temperature ] protect moisture .",
    "adverseReactions": "sevelamer hydrochloride tablets contraindicated patients bowel obstruction . sevelamer hydrochloride tablets contraindicated patients known hypersensitivity sevelamer hydrochloride excipients .",
    "indications_original": "Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of sevelamer hydrochloride tablets in CKD patients who are not on dialysis have not been studied.",
    "contraindications_original": "Patients Not Taking a Phosphate Binder. The recommended starting dose of sevelamer hydrochloride tablets is 800 mg to 1600 mg orally, which can be administered as one or two 800 mg sevelamer hydrochloride tablets with meals based on serum phosphorus level. Table 1 provides recommended starting doses of sevelamer hydrochloride tablets for patients not taking a phosphate binder.\n                  \n                       Table 1: Starting Dose for Dialysis Patients Not Taking a Phosphate Binder \n                     \n                     \n                     \n                        \n                           \n                               Serum Phosphorus\n                              \n                           \n                           \n                               Sevelamer Hydrochloride Tablets 800 mg\n                              \n                           \n                        \n                        \n                            >5.5 and <7.5 mg/dL\n                           \n                            1 tablet three times daily with meals\n                           \n                        \n                        \n                            ≥7.5 and <9.0 mg/dL\n                           \n                            2 tablets three times daily with meals\n                           \n                        \n                        \n                            ≥9.0 mg/dL\n                           \n                            2 tablets three times daily with meals\n                           \n                        \n                     \n                  \n                  \n                     Patients Switching from Calcium Acetate. In a study in 84 CKD patients on hemodialysis, a similar reduction in serum phosphorus was seen with equivalent doses (approximately mg for mg) of sevelamer hydrochloride tablets and calcium acetate. Table 2 gives recommended starting doses of sevelamer hydrochloride tablets based on a patient's current calcium acetate dose.\n                  \n                       Table 2: Starting Dose for Dialysis Patients Switching from Calcium Acetate to Sevelamer Hydrochloride Tablets \n                     \n                     \n                     \n                        \n                           \n                               Calcium Acetate 667 mg\n                              \n                               (Tablets per meal)\n                              \n                           \n                           \n                               Sevelamer Hydrochloride Tablets 800 mg\n                              \n                               (Tablets per meal)\n                              \n                           \n                        \n                        \n                            1 tablet\n                           \n                            1 tablet \n                           \n                        \n                        \n                            2 tablets\n                           \n                            2 tablets\n                           \n                        \n                        \n                            3 tablets \n                           \n                            3 tablets \n                           \n                        \n                     \n                  \n                  \n                     Dose Titration for All Patients Taking Sevelamer Hydrochloride Tablets. Adjust dosage based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dL or less. Increase or decrease by one tablet per meal at two-week intervals as necessary. Table 3 gives a dose titration guideline. The average dose in a Phase 3 trial designed to lower serum phosphorus to 5.0 mg/dL or less was approximately three sevelamer hydrochloride 800 mg tablets per meal. The maximum average daily sevelamer hydrochloride tablets dose studied was 13 g.\n                  \n                       Table 3: Dose Titration Guideline \n                     \n                     \n                     \n                        \n                           \n                               Serum Phosphorus\n                              \n                           \n                           \n                               Sevelamer Hydrochloride Tablets Dose\n                              \n                           \n                        \n                        \n                            >5.5 mg/dL\n                           \n                            Increase 1 tablet per meal at 2-week intervals\n                           \n                        \n                        \n                            3.5-5.5 mg/dL\n                           \n                            Maintain current dose\n                           \n                        \n                        \n                            <3.5 mg/dL\n                           \n                            Decrease 1 tablet per meal",
    "warningsAndPrecautions_original": "Sevelamer hydrochloride tablets are supplied as white to off-white, oval shaped film-coated tablets, debossed with \"NAV\" on one side and debossed with \"110\" on other side.\n                  Sevelamer hydrochloride tablets 800 mg are packaged in bottles of 180 tablets.\n                  1 Bottle of 180 counts 800 mg Tablets (NDC 70710-2058-8)\n                  \n                     Storage: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).\n                  Do not use sevelamer hydrochloride tablets after the expiration date on the bottle.\n                  [See USP controlled room temperature]\n                  Protect from moisture.",
    "adverseReactions_original": "Sevelamer hydrochloride tablets are contraindicated in patients with bowel obstruction.\n                  Sevelamer hydrochloride tablets are contraindicated in patients with known hypersensitivity to sevelamer hydrochloride or to any of the excipients."
}